This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.
Wright Medical (WMGI) Earnings Beat in Q2, Guidance Slashed
by Zacks Equity Research
Wright Medical (WMGI) gains from Upper and Lower Extremities units in Q2; slashes 2019 view.
Cardiovascular Systems (CSII) Earnings Match Estimates in Q4
by Zacks Equity Research
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance
by Zacks Equity Research
CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.
Avanos (AVNS) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Avanos (AVNS) second-quarter results benefit from higher revenues, strong segmental performance and expansion in margins.
AMN Healthcare (AMN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) issues upbeat revenue guidance for the third quarter of 2019.
Syneos Health (SYNH) Q2 Earnings Beat Estimates, '19 View Up
by Zacks Equity Research
We are upbeat about Syneos Health's (SYNH) strong year-over-year revenue growth across both operating segments.
Insulet (PODD) Misses on Q2 Earnings, Ups '19 Revenue View
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.
STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.
Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.
Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues
by Zacks Equity Research
Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.
Hill-Rom (HRC) Beats on Q3 Earnings, Tightens '19 Guidance
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year increase in revenues on robust domestic growth.
Integer Holdings (ITGR) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Higher revenues and strong 2019 outlook benefit Integer Holdings' (ITGR) Q2 earnings.
HMS Holdings (HMSY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues, gross margin expansion and raised 2019 outlook benefit HMS Holdings' (HMSY) Q2 earnings.
Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss
by Zacks Equity Research
Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.
PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed
by Zacks Equity Research
PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up
by Zacks Equity Research
Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.
Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results
by Zacks Equity Research
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.
DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.
DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.
Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.